Insulet (Nasdaq:PODD) announced today that it partnered with Marvel to launch a comic book featuring a hero with type 1 diabetes. The companies collaborated on the comic to help make people with diabetes feel seen, understood and represented. This marks another initiative for the Acton, Massachusetts-based automated insulin pump maker to promote inclusivity and representation. […]
Insulet
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]
Insulet stock rises on Street-beating Q1, 29% sales uptick
Insulet’s (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast. Shares of PODD were trading at around $307 a share near the close of trading, the day after the company’s evening earnings report. The Acton, Massachusetts–based automated insulin delivery technology maker reported profits of $35.4 million. That equals 50¢ per […]
Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction
A judge has issued a permanent injunction, signaling an Insulet (Nasdaq:PODD) victory in a trade secret case against EOFlow. The permanent injunction highlights the successful defense of Insulet’s intellectual property. Subsequently, the damages award was reduced from $452 million to $60 million at Insulet’s election. The company wanted the permanent injunction instead of the higher […]
Ashley McEvoy named president and CEO at Insulet
Insulet (Nasdaq:PODD) announced today that its board of directors appointed Ashley McEvoy as president and CEO, effective immediately. McEvoy, a longtime Johnson & Johnson MedTech executive, also joins the company’s board. She succeeds Jim Hollingshead in the corner office of the Acton, Massachusetts-based automated insulin delivery technology developer. Hollingshead agreed with Insulet’s board that his […]
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
Insulet launches Omnipod 5 in Canada
Insulet (Nasdaq:PODD) announced today that it commercially launched the Omnipod 5 automated insulin delivery (AID) system in Canada. The first tubeless, waterproof AID system is approved in Canada for people with type 1 diabetes ages two years and above. In Canada, it pairs with the Dexcom G6 and G7 continuous glucose monitor (CGM) systems to […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Insulet study shows improvements with Omnipod 5 transitioning from multiple daily injections
Insulet (Nasdaq:PODD) today announced new Omnipod 5 clinical data highlighting the transition from multiple daily injections (MDI). Investigators shared data from the RADIANT study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. The randomized controlled trial evaluated the direct transition from MDI to automated insulin delivery (AID). Insulet […]
Insulet CTO Mark Field departs for new opportunities
Insulet (Nasdaq:PODD) announced today that SVP and Chief Technology Officer Mark Field is departing the company. Field left the automated insulin delivery technology developer to pursue other opportunities, effective March 14, according to an SEC filing. As the company searches for Field’s successor, it tapped Amit Guliani to hold the post of interim CTO, effective […]
